Financial Comparison: Rocket One Inc. Common Stock (NASDAQ:RKTO) and Lasertec (OTCMKTS:LSRCY)

Lasertec (OTCMKTS:LSRCY) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Lasertec and Rocket One Inc. Common Stock, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lasertec	0	0	0	1	4.00
Rocket One Inc. Common Stock	1	0	1	0	2.00

Rocket One Inc. Common Stock has a consensus price target of $5.00, indicating a potential upside of 528.30%. Given Rocket One Inc. Common Stock’s higher possible upside, analysts plainly believe Rocket One Inc. Common Stock is more favorable than Lasertec.

Institutional & Insider Ownership

7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Lasertec and Rocket One Inc. Common Stock”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lasertec	N/A	N/A	N/A	N/A	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47 million	($0.80)	-0.99

Profitability

This table compares Lasertec and Rocket One Inc. Common Stock’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lasertec	N/A	N/A	N/A
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

About Lasertec

Lasertec Corporation engages in the designing, manufacturing, and sale of inspection and measurement equipment in Japan and internationally. The company offers semiconductor related products, which includes mask related systems for extreme ultraviolet and deep ultraviolet solutions, and wafers inspection and review systems; and FPD photomask inspection systems. It also provides laser microscopes, electro-chemical reaction visualizing confocal, and coating thickness scanning system; and in-situ observation at ultra high temperature confocal scanning laser microscope. The company was formerly known as NJS Corporation and changed its name to Lasertec Corporation in 1986. Lasertec Corporation was founded in 1960 and is headquartered in Yokohama, Japan.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.